Biossance

Trace the money far enough and you arrive at malaria, not moisturizer. The lab behind this label, Amyris, spun out of the University of California, Berkeley in 2003, and its breakthrough had nothing to do with faces. In 2005 the Bill & Melinda Gates Foundation handed the scientists roughly $42.5 million to attack a brutal problem: artemisinin, the most effective antimalarial drug, was painstakingly extracted from sweet wormwood and chronically in short supply. The Berkeley team re-engineered yeast to ferment plant sugars into artemisinic acid, a precursor to the drug, and over the following years that fermentation platform helped deliver well over a hundred million antimalarial treatments to the developing world.

The same trick that brewed a medicine could brew almost any molecule. Amyris chased renewable diesel and jet fuel, stumbled when oil prices collapsed, then pivoted toward higher-value flavors and fragrances. One molecule its yeast made beautifully was squalane, a featherlight emollient that for decades had been wrung from shark liver, an ugly supply chain that killed millions of deep-sea sharks a year. Fermenting it from sugar instead was both cleaner chemistry and a marketing gift.

What made the squalane noteworthy wasn't novelty but identity: the fermented version is molecularly indistinguishable from the shark- or olive-derived kind, so it behaves exactly the same on skin while sidestepping the slaughter. That single ingredient became the spine of an entire range, from face oils to eye creams. The catch, then and now, is that elegant sourcing and a genuinely good emollient don't equal active-driven treatment; the formulas are pleasant, gentle, and competently built rather than clinically transformative. Read it as smart green chemistry and reliable hydration, born from a fermentation tank originally meant to save lives, not as a miracle in a dropper.

Sources:[1][2][3]